title: Serological evidence for hepatitis E virus infection in Israel.
abstract: Israel is suspected to be endemic for hepatitis E virus (HEV) because of its geographic location and the large-scale immigration from endemic countries. Although no cases of local HEV infection have been diagnosed, a serological survey would provide indirect evidence for such infection. We examined sera from 1,416 healthy subjects, including 1,139 Jews from various regions of Israel and 277 Arabs, most of whom reside in the West Bank of the Jordan River. In addition, we tested 13 non-A, non-B, and non-C viral hepatitis patients. Sera were screened for antibody to hepatitis E virus (anti-HEV) by a newly developed enzyme immunoassay (EIA) and by immunoblots for both IgG and IgM anti-HEV activity. Positive samples were confirmed by neutralization. The seroprevalence found by EIA was 2.81% and 1.81% in the Jewish and Arab populations, respectively. More than a 2-fold higher prevalence in males compared to females and an increase with age were found in both populations. However, these differences were nonsignificant. The geographical distribution was even throughout the country, except for two clusters of 3 and 4 seropositive individuals possibly reflecting past foci of infection. Eight of 37 EIA-positive sera were positive for IgG, and 3 were positive for IgM by the immunoblot assay. Among hepatitis patients (9 acute and 4 chronic), one patient with chronic hepatitis was positive for both IgG and IgM. Our study provides indirect evidence that Israel is endemic for HEV.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Central Virology Laboratory, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
authors.forename: Y V
authors.initials: YV
authors.lastname: Karetnyi
authors.forename: M O
authors.initials: MO
authors.lastname: Favorov
authors.forename: N S
authors.initials: NS
authors.lastname: Khudyakova
authors.forename: P
authors.initials: P
authors.lastname: Weiss
authors.forename: S
authors.initials: S
authors.lastname: Bar-Shani
authors.forename: R
authors.initials: R
authors.lastname: Handsher
authors.forename: Y
authors.initials: Y
authors.lastname: Aboudy
authors.forename: N
authors.initials: N
authors.lastname: Varsano
authors.forename: E
authors.initials: E
authors.lastname: Schwartz
authors.forename: E
authors.initials: E
authors.lastname: Levin
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D002648:Child; D002675:Child, Preschool; D005260:Female; D006508:Hepatitis Antibodies / Q000097:blood; D016751:Hepatitis E / Q000453:epidemiology* / Q000276:immunology; D016752:Hepatitis E virus / Q000276:immunology; D006521:Hepatitis, Chronic / Q000453:epidemiology / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D007223:Infant; D007557:Israel / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D016036:Seroepidemiologic Studies; D012737:Sex Factors
chemical_list: D006508:Hepatitis Antibodies; D007074:Immunoglobulin G; D007075:Immunoglobulin M